A pilot study of cisplatin and etoposide with and without radiotherapy for advanced malignant thymoma
Thymoma is a rare neoplasm of the mediastinum, for which very few data on the efficacy and safety of chemotherapy and chemoradiotherapy are available. The objective of this pilot study was to assess the safety and efficacy of cisplatin, etoposide, and radiotherapy for thymoma. Patients with advanced...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2014-04, Vol.34 (4), p.2023-2027 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2027 |
|---|---|
| container_issue | 4 |
| container_start_page | 2023 |
| container_title | Anticancer research |
| container_volume | 34 |
| creator | Tamiya, Akihiro Matsumura, Akihide Tsuji, Taisuke Morimoto, Masahiro Asami, Kazuhiro Okishio, Kyoichi Shimizu, Shigeki Yoon, Hyung-Eun Atagi, Shinji Akira, Masanori Kitaichi, Masanori Kawaguchi, Tomoya |
| description | Thymoma is a rare neoplasm of the mediastinum, for which very few data on the efficacy and safety of chemotherapy and chemoradiotherapy are available. The objective of this pilot study was to assess the safety and efficacy of cisplatin, etoposide, and radiotherapy for thymoma.
Patients with advanced, previously-untreated thymoma (Masaoka classification), measurable disease, and a performance status of 0-2 were eligible, and were treated with cisplatin-plus-etoposide, together with radiotherapy when possible.
One patient achieved complete response, and seven achieved partial responses. Progression-free survival was 37.7 months (95% confidence interval = 18.6-56.8 months). Ten patients had grade 4 neutropenia, and five patients had grade 3 febrile neutropenia. However, other toxicities were relatively mild. To date, only five patients (45.5%) have died, and the median survival time is 128.1 months (95% confidence interval = 51.6-204.6 months). Patients treated with chemoradiotherapy had a good response and long progression-free survival.
The combination of cisplatin and etoposide with or without radiotherapy is effective for advanced thymoma, and has an acceptable toxicity. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1512560428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1512560428</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-60562226b96fdf5908047ef91e916c3f4b181352a306a8a0537749a04ef8d1e53</originalsourceid><addsrcrecordid>eNo1kEtLxDAUhYMgzjj6FyRLN4W82yyHwRcIbnRd7jQ3TqRtYpMq_fe-xtX5OHycxTkha15bXtVashU5z_mNMWNsI8_ISihjRa3EmuCWptDHQnOZ3UKjp13IqYcSRgqjo1hiijk4pJ-hHH6rH4hzoRO4EMsBJ0gL9XGi4D5g7NDRAfrwOsJYaDksQxzggpx66DNeHnNDXm5vnnf31ePT3cNu-1glwXmpDNNGCGH21njntWUNUzV6y9Fy00mv9rzhUguQzEADTMu6VhaYQt84jlpuyPXfbpri-4y5tEPIHfY9jBjn3HLNhTZMieZbvTqq835A16YpDDAt7f818gtOqV83</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1512560428</pqid></control><display><type>article</type><title>A pilot study of cisplatin and etoposide with and without radiotherapy for advanced malignant thymoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Tamiya, Akihiro ; Matsumura, Akihide ; Tsuji, Taisuke ; Morimoto, Masahiro ; Asami, Kazuhiro ; Okishio, Kyoichi ; Shimizu, Shigeki ; Yoon, Hyung-Eun ; Atagi, Shinji ; Akira, Masanori ; Kitaichi, Masanori ; Kawaguchi, Tomoya</creator><creatorcontrib>Tamiya, Akihiro ; Matsumura, Akihide ; Tsuji, Taisuke ; Morimoto, Masahiro ; Asami, Kazuhiro ; Okishio, Kyoichi ; Shimizu, Shigeki ; Yoon, Hyung-Eun ; Atagi, Shinji ; Akira, Masanori ; Kitaichi, Masanori ; Kawaguchi, Tomoya</creatorcontrib><description>Thymoma is a rare neoplasm of the mediastinum, for which very few data on the efficacy and safety of chemotherapy and chemoradiotherapy are available. The objective of this pilot study was to assess the safety and efficacy of cisplatin, etoposide, and radiotherapy for thymoma.
Patients with advanced, previously-untreated thymoma (Masaoka classification), measurable disease, and a performance status of 0-2 were eligible, and were treated with cisplatin-plus-etoposide, together with radiotherapy when possible.
One patient achieved complete response, and seven achieved partial responses. Progression-free survival was 37.7 months (95% confidence interval = 18.6-56.8 months). Ten patients had grade 4 neutropenia, and five patients had grade 3 febrile neutropenia. However, other toxicities were relatively mild. To date, only five patients (45.5%) have died, and the median survival time is 128.1 months (95% confidence interval = 51.6-204.6 months). Patients treated with chemoradiotherapy had a good response and long progression-free survival.
The combination of cisplatin and etoposide with or without radiotherapy is effective for advanced thymoma, and has an acceptable toxicity.</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 24692742</identifier><language>eng</language><publisher>Greece</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemoradiotherapy - adverse effects ; Cisplatin - administration & dosage ; Combined Modality Therapy - adverse effects ; Etoposide - administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Pilot Projects ; Thymoma - drug therapy ; Thymoma - mortality ; Thymoma - pathology ; Thymoma - radiotherapy ; Treatment Outcome</subject><ispartof>Anticancer research, 2014-04, Vol.34 (4), p.2023-2027</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24692742$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tamiya, Akihiro</creatorcontrib><creatorcontrib>Matsumura, Akihide</creatorcontrib><creatorcontrib>Tsuji, Taisuke</creatorcontrib><creatorcontrib>Morimoto, Masahiro</creatorcontrib><creatorcontrib>Asami, Kazuhiro</creatorcontrib><creatorcontrib>Okishio, Kyoichi</creatorcontrib><creatorcontrib>Shimizu, Shigeki</creatorcontrib><creatorcontrib>Yoon, Hyung-Eun</creatorcontrib><creatorcontrib>Atagi, Shinji</creatorcontrib><creatorcontrib>Akira, Masanori</creatorcontrib><creatorcontrib>Kitaichi, Masanori</creatorcontrib><creatorcontrib>Kawaguchi, Tomoya</creatorcontrib><title>A pilot study of cisplatin and etoposide with and without radiotherapy for advanced malignant thymoma</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Thymoma is a rare neoplasm of the mediastinum, for which very few data on the efficacy and safety of chemotherapy and chemoradiotherapy are available. The objective of this pilot study was to assess the safety and efficacy of cisplatin, etoposide, and radiotherapy for thymoma.
Patients with advanced, previously-untreated thymoma (Masaoka classification), measurable disease, and a performance status of 0-2 were eligible, and were treated with cisplatin-plus-etoposide, together with radiotherapy when possible.
One patient achieved complete response, and seven achieved partial responses. Progression-free survival was 37.7 months (95% confidence interval = 18.6-56.8 months). Ten patients had grade 4 neutropenia, and five patients had grade 3 febrile neutropenia. However, other toxicities were relatively mild. To date, only five patients (45.5%) have died, and the median survival time is 128.1 months (95% confidence interval = 51.6-204.6 months). Patients treated with chemoradiotherapy had a good response and long progression-free survival.
The combination of cisplatin and etoposide with or without radiotherapy is effective for advanced thymoma, and has an acceptable toxicity.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Chemoradiotherapy - adverse effects</subject><subject>Cisplatin - administration & dosage</subject><subject>Combined Modality Therapy - adverse effects</subject><subject>Etoposide - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Pilot Projects</subject><subject>Thymoma - drug therapy</subject><subject>Thymoma - mortality</subject><subject>Thymoma - pathology</subject><subject>Thymoma - radiotherapy</subject><subject>Treatment Outcome</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtLxDAUhYMgzjj6FyRLN4W82yyHwRcIbnRd7jQ3TqRtYpMq_fe-xtX5OHycxTkha15bXtVashU5z_mNMWNsI8_ISihjRa3EmuCWptDHQnOZ3UKjp13IqYcSRgqjo1hiijk4pJ-hHH6rH4hzoRO4EMsBJ0gL9XGi4D5g7NDRAfrwOsJYaDksQxzggpx66DNeHnNDXm5vnnf31ePT3cNu-1glwXmpDNNGCGH21njntWUNUzV6y9Fy00mv9rzhUguQzEADTMu6VhaYQt84jlpuyPXfbpri-4y5tEPIHfY9jBjn3HLNhTZMieZbvTqq835A16YpDDAt7f818gtOqV83</recordid><startdate>201404</startdate><enddate>201404</enddate><creator>Tamiya, Akihiro</creator><creator>Matsumura, Akihide</creator><creator>Tsuji, Taisuke</creator><creator>Morimoto, Masahiro</creator><creator>Asami, Kazuhiro</creator><creator>Okishio, Kyoichi</creator><creator>Shimizu, Shigeki</creator><creator>Yoon, Hyung-Eun</creator><creator>Atagi, Shinji</creator><creator>Akira, Masanori</creator><creator>Kitaichi, Masanori</creator><creator>Kawaguchi, Tomoya</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201404</creationdate><title>A pilot study of cisplatin and etoposide with and without radiotherapy for advanced malignant thymoma</title><author>Tamiya, Akihiro ; Matsumura, Akihide ; Tsuji, Taisuke ; Morimoto, Masahiro ; Asami, Kazuhiro ; Okishio, Kyoichi ; Shimizu, Shigeki ; Yoon, Hyung-Eun ; Atagi, Shinji ; Akira, Masanori ; Kitaichi, Masanori ; Kawaguchi, Tomoya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-60562226b96fdf5908047ef91e916c3f4b181352a306a8a0537749a04ef8d1e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Chemoradiotherapy - adverse effects</topic><topic>Cisplatin - administration & dosage</topic><topic>Combined Modality Therapy - adverse effects</topic><topic>Etoposide - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Pilot Projects</topic><topic>Thymoma - drug therapy</topic><topic>Thymoma - mortality</topic><topic>Thymoma - pathology</topic><topic>Thymoma - radiotherapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tamiya, Akihiro</creatorcontrib><creatorcontrib>Matsumura, Akihide</creatorcontrib><creatorcontrib>Tsuji, Taisuke</creatorcontrib><creatorcontrib>Morimoto, Masahiro</creatorcontrib><creatorcontrib>Asami, Kazuhiro</creatorcontrib><creatorcontrib>Okishio, Kyoichi</creatorcontrib><creatorcontrib>Shimizu, Shigeki</creatorcontrib><creatorcontrib>Yoon, Hyung-Eun</creatorcontrib><creatorcontrib>Atagi, Shinji</creatorcontrib><creatorcontrib>Akira, Masanori</creatorcontrib><creatorcontrib>Kitaichi, Masanori</creatorcontrib><creatorcontrib>Kawaguchi, Tomoya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamiya, Akihiro</au><au>Matsumura, Akihide</au><au>Tsuji, Taisuke</au><au>Morimoto, Masahiro</au><au>Asami, Kazuhiro</au><au>Okishio, Kyoichi</au><au>Shimizu, Shigeki</au><au>Yoon, Hyung-Eun</au><au>Atagi, Shinji</au><au>Akira, Masanori</au><au>Kitaichi, Masanori</au><au>Kawaguchi, Tomoya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A pilot study of cisplatin and etoposide with and without radiotherapy for advanced malignant thymoma</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2014-04</date><risdate>2014</risdate><volume>34</volume><issue>4</issue><spage>2023</spage><epage>2027</epage><pages>2023-2027</pages><eissn>1791-7530</eissn><abstract>Thymoma is a rare neoplasm of the mediastinum, for which very few data on the efficacy and safety of chemotherapy and chemoradiotherapy are available. The objective of this pilot study was to assess the safety and efficacy of cisplatin, etoposide, and radiotherapy for thymoma.
Patients with advanced, previously-untreated thymoma (Masaoka classification), measurable disease, and a performance status of 0-2 were eligible, and were treated with cisplatin-plus-etoposide, together with radiotherapy when possible.
One patient achieved complete response, and seven achieved partial responses. Progression-free survival was 37.7 months (95% confidence interval = 18.6-56.8 months). Ten patients had grade 4 neutropenia, and five patients had grade 3 febrile neutropenia. However, other toxicities were relatively mild. To date, only five patients (45.5%) have died, and the median survival time is 128.1 months (95% confidence interval = 51.6-204.6 months). Patients treated with chemoradiotherapy had a good response and long progression-free survival.
The combination of cisplatin and etoposide with or without radiotherapy is effective for advanced thymoma, and has an acceptable toxicity.</abstract><cop>Greece</cop><pmid>24692742</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7530 |
| ispartof | Anticancer research, 2014-04, Vol.34 (4), p.2023-2027 |
| issn | 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1512560428 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemoradiotherapy - adverse effects Cisplatin - administration & dosage Combined Modality Therapy - adverse effects Etoposide - administration & dosage Female Humans Male Middle Aged Neoplasm Staging Pilot Projects Thymoma - drug therapy Thymoma - mortality Thymoma - pathology Thymoma - radiotherapy Treatment Outcome |
| title | A pilot study of cisplatin and etoposide with and without radiotherapy for advanced malignant thymoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T18%3A51%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20pilot%20study%20of%20cisplatin%20and%20etoposide%20with%20and%20without%20radiotherapy%20for%20advanced%20malignant%20thymoma&rft.jtitle=Anticancer%20research&rft.au=Tamiya,%20Akihiro&rft.date=2014-04&rft.volume=34&rft.issue=4&rft.spage=2023&rft.epage=2027&rft.pages=2023-2027&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1512560428%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1512560428&rft_id=info:pmid/24692742&rfr_iscdi=true |